1. Lipocine will present at H.C. Wainwright conference on September 8-10. 2. Investors can meet Lipocine management regarding clinical developments and partnerships. 3. LPCN's drug candidates target large markets with unmet medical needs. 4. Key products include LPCN 1154 for postpartum depression and LPCN 2401 for obesity. 5. FDA-approved TLANDO increases potential visibility and credibility for LPCN.
Positive engagement at investment conferences historically leads to increased investor interest, benefiting stock prices.
The presentation focuses on LPCN's innovative products, likely attracting investor attention and partnership opportunities.
Investor presentations can lead to immediate interest and potential short-term stock price movements.
SALT LAKE CITY, Sept. 5, 2025 /PRNewswire/ -- Lipocine Inc. (NASDAQ:LPCN), a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with effective oral delivery, today announced that Company Management will present and meet with investors at the H.C. Wainwright 27th Annual Global Investment Conference being held in-person and virtually on September 8-10, 2025.
Presentation Details
Time: Available from 7:00 a.m. EDT onwards
Date: Friday, September 5, 2025
Investors can register for the conference here. Those interested in arranging a 1x1 meeting with Lipocine should contact their H.C. Wainwright representative.
About Lipocine
Lipocine is a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with effective oral delivery. Lipocine has drug candidates in development as well as drug candidates for which we are exploring partnerships. Our drug candidates represent enablement of differentiated, patient friendly oral delivery options for favorable benefit to risk profile which target large addressable markets with significant unmet medical needs.
Lipocine's clinical development candidates include: LPCN 1154, oral brexanolone, for the potential treatment of postpartum depression, LPCN 2101 for the potential treatment of epilepsy, LPCN 2203 an oral candidate targeted for the management of essential tremor, LPCN 2401 an oral proprietary anabolic androgen receptor agonist, as an adjunct therapy to incretin mimetics, as an aid for improved body composition in obesity management and LPCN 1148, a novel androgen receptor agonist prodrug for oral administration targeted for the management of symptoms associated with liver cirrhosis. Lipocine is exploring partnering opportunities for LPCN 1107, our candidate for prevention of preterm birth, LPCN 1154, for rapid relief of postpartum depression, LPCN 2401 for obesity management, LPCN 1148, for the management of decompensated cirrhosis, and LPCN 1144, our candidate for treatment of metabolic dysfunction-associated steatohepatitis (MASH). TLANDO, a novel oral prodrug of testosterone containing testosterone undecanoate developed by Lipocine, is approved by the FDA for conditions associated with a deficiency of endogenous testosterone, also known as hypogonadism, in adult males. For more information, please visit www.lipocine.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/lipocine-to-present-at-hc-wainwright-27th-annual-global-investment-conference-302547924.html
SOURCE Lipocine Inc.